# Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

> **NCT02718950** · PHASE3 · UNKNOWN · sponsor: **University of Campinas, Brazil** · enrollment: 20 (estimated)

## Conditions studied

- Obesity
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Liraglutide 3.0 mg

## Key facts

- **NCT ID:** NCT02718950
- **Lead sponsor:** University of Campinas, Brazil
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-03
- **Final completion:** 2017-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02718950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02718950, "Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02718950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*